EUCTR2004-002353-31-DK进行中（未招募）1 期
A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancer
Organisation name was not entered0 个研究点目标入组 60 人开始时间: 2008年7月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Histological documented prostate carcinoma
- •Hormonrefractary disease
- •Metastatic disease
- •PSA>10 microg/l
- •Progressive rise in PSA in two measurement (>25%)
- •Castrate level of testosterone
- •Performance status <=2
- •No prior treatment with estrogens or prednisolon for prostate cancer
- •No radionucleid treatment
- •No concurrent bisphosphonates
- •No prior systemic chemotherapy
- •Acceptable liver, hematological and renal function
- •Signed informed consent
- •>18 years old
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Radiotherapy involving more than 25% of bonemarrow area
- •Other or prior malignant disease except squamous cell skin cancer.
研究者
相似试验
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer - SF- 2Gem/taxoncological patients onlyMedDRA version: 6.1Level: PTClassification code 10055113EUCTR2005-006168-71-ITA.S.L. 270
招募中
2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomasadvanced bone and soft tissue sarcomasJPRN-UMIN000031004Kobe University20
招募中
2 期
GD therapy for advanced sarcomasadvanced pretreated bone and soft tissue sarcomasJPRN-jRCTs051180042Hara Hitomi20
进行中（未招募）
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70
招募中
2 期
Study of gemcitabine docetaxel in synovial sarcoma in relapsed metastatic settingCTRI/2020/02/023612Department of Medical Oncology